Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This protocol is to provide continuing medical/surgical/radio-therapeutic care, treatment and follow-up for NCI patients not currently entered on an active research protocol. No investigational treatments will be administered on this protocol.
| Condition |
|---|
|
Acquired Immunodeficiency Syndrome Neoplasm Skin Disease HIV Infections |
| Study Type: | Observational |
| Official Title: | Continuing Treatment for Children and Adults in the Center for Cancer Research |
| Estimated Enrollment: | 99999999 |
| Study Start Date: | January 1992 |
Background:
It may be in the interest of the CCR to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol.
Objective:
To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol.
Eligibility:
Subjects who have been previously enrolled on and received treatment according to an approved CCR research protocol. (clinical trial)
It is in the best interest of the subject and the CCR for the subject to continue to receive standard care and follow-up at the NIH.
Design:
Medical/surgical/radiotherapeutic care, treatment and follow-up is provided for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on an active research protocol.
No investigational treatments will be administered. This protocol is not be used as a platform to perform pilot studies of off-label uses for standard agents.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
Subjects of any age who have been previously enrolled and treated on an approved CCR research treatment protocol.
It is in the best interests of the subject and the CCR for the subject to continue to receive treatment and follow-up at the NIH.
The subject or guardian signs the informed consent and agrees to the proposed treatment regimen.
EXCLUSION CRITERIA:
Subjects who have not been previously treated on a CCR research treatment protocol.
Subjects who are receiving an investigational therapy.
Contacts and Locations| Contact: Caryn Steakley, R.N. | (301) 435-3685 | steaklec@mail.nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937 | |
| Principal Investigator: | Caryn Steakley, R.N. | National Cancer Institute (NCI) |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00001295 History of Changes |
| Other Study ID Numbers: | 920094, 92-C-0094 |
| Study First Received: | November 3, 1999 |
| Last Updated: | December 1, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Standard Care Follow-Up Bridge Protocol |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome HIV Infections Neoplasms Immunologic Deficiency Syndromes Skin Diseases Lentivirus Infections Retroviridae Infections |
RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on February 26, 2013
